Intézmény

Sinclair Dermatology

East Melbourne, AusztráliaHonlap

9futó vizsgálat
18lezárt vizsgálat
357publikáció (OpenAlex)

Futó vizsgálatok

Toboroz
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
NCT07772492· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
NCT07244263· 2. fázis· Takeda· Forrás
Fut, nem toboroz
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· 3. fázis· Alumis Inc· Forrás
Fut, nem toboroz
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT06143878· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
NCT05995964· 2. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182· 3. fázis· AbbVie· Forrás
Toboroz
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198· 3. fázis· Eli Lilly and Company· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Alopecia areata2 toboroz

Lezárt vizsgálatok

Lezárult
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
NCT06586112· 3. fázis· Alumis Inc· Forrás
Lezárult
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
NCT06333860· 4. fázis· AbbVie· Forrás
Leállították
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
NCT06113328· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
NCT06088043· 3. fázis· Takeda· Forrás
Lezárult
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06046729· 2. fázis· Eli Lilly and Company· Forrás
Lezárult
Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
NCT05589610· 2. fázis· Equillium· Forrás
Lezárult
A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
NCT05651711· 3. fázis· Amgen· Forrás
Lezárult
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05601882· 3. fázis· AbbVie· Forrás
Lezárult
A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis
NCT05081557· AbbVie· Forrás
Lezárult
A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis
NCT04911751· 2. fázis· KoBioLabs· Forrás
Leállították
PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA
NCT04517864· 2. fázis· Pfizer· Forrás
Lezárult
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
NCT04392154· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
NCT04036435· 3. fázis· Bristol-Myers Squibb· Forrás
Lezárult
Long-Term PF-06651600 for the Treatment of Alopecia Areata
NCT04006457· 3. fázis· Pfizer· Forrás
Lezárult
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
NCT03899259· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
NCT03607422· 3. fázis· AbbVie· Forrás
Lezárult
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT03422822· 3. fázis· Pfizer· Forrás
Lezárult
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
NCT03047395· 3. fázis· AbbVie· Forrás

Regiszterbeli névváltozatok (13)

A vizsgálati regiszterek ezeken a neveken tartják nyilván az intézményt. Minden sor egy regiszterbejegyzés: a címe és az alatta nyilvántartott vizsgálatok.

Sinclair Dermatology
East Melbourne, 3002
11 vizsgálat
Sinclair Dermatology
Melbourne, Victoria 3002
4 vizsgálat
Sinclair Dermatology-East Melbourne
East Melbourne, Victoria 3002
2 vizsgálat
- NCT06088043A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
- NCT06046729A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Sinclair Dermatology /ID# 217791
East Melbourne, Victoria 3002
1 vizsgálat
- NCT03607422A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
Sinclair Dermatology - Melbourne /ID# 154310
Melbourne, Victoria 3995
1 vizsgálat
- NCT03047395A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
Sinclair Dermatology - Melbourne /ID# 242163
East Melbourne, Victoria 3002
1 vizsgálat
- NCT05081557A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis
Sinclair Dermatology - Melbourne /ID# 249937
East Melbourne, Victoria 3002
1 vizsgálat
- NCT05601882A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Sinclair Dermatology - Melbourne /ID# 254412
East Melbourne, Victoria 3002
1 vizsgálat
- NCT05889182A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Sinclair Dermatology - Melbourne /ID# 258565
East Melbourne, Victoria 3002
1 vizsgálat
- NCT06012240A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Sinclair Dermatology - Melbourne /ID# 262997
East Melbourne, Victoria 3002
1 vizsgálat
- NCT06333860A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
Sinclair Dermatology - Melbourne /ID# 263121
East Melbourne, Victoria 3002
1 vizsgálat
- NCT06468228A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Sinclair Dermatology - Melbourne /ID# 283854
East Melbourne, Victoria 3002
1 vizsgálat
- NCT07772492A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
Sinclair Dermatology (Site 1704)
Melbourne, Victoria 3002
1 vizsgálat
- NCT06113328A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

Alopecia areata18 munka · 7 vizsgálat

Intézményadatok: ROR 043sz6670 (CC0-1.0)Frissítve: 2026. nov. 12.

Hibát jelzek